| __timestamp | Bristol-Myers Squibb Company | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 2999000 |
| Thursday, January 1, 2015 | 5001000000 | 10393000 |
| Friday, January 1, 2016 | 5002000000 | 15994000 |
| Sunday, January 1, 2017 | 4849000000 | 26975000 |
| Monday, January 1, 2018 | 4551000000 | 39509000 |
| Tuesday, January 1, 2019 | 4871000000 | 48869000 |
| Wednesday, January 1, 2020 | 7661000000 | 42510000 |
| Friday, January 1, 2021 | 7690000000 | 46105000 |
| Saturday, January 1, 2022 | 7814000000 | 50513000 |
| Sunday, January 1, 2023 | 7772000000 | 51292000 |
| Monday, January 1, 2024 | 8414000000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Bristol-Myers Squibb Company, a giant in the sector, has consistently managed its SG&A expenses, averaging around $6 billion annually from 2014 to 2023. Notably, their expenses peaked in 2022, reflecting strategic investments. In contrast, Wave Life Sciences Ltd., a smaller player, has seen a steady increase in SG&A expenses, growing by over 1,600% from 2014 to 2023. This growth highlights their aggressive expansion strategy. While Bristol-Myers Squibb's expenses are significantly higher, the efficiency of their spending is evident in their market dominance. Wave Life Sciences, with its leaner budget, focuses on innovation and niche markets. This comparison underscores the diverse strategies companies employ to balance growth and operational efficiency.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Wave Life Sciences Ltd.
BeiGene, Ltd. or Wave Life Sciences Ltd.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Genmab A/S and Wave Life Sciences Ltd.
Neurocrine Biosciences, Inc. and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Incyte Corporation vs Wave Life Sciences Ltd.: SG&A Expense Trends
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Wave Life Sciences Ltd. and Novavax, Inc.: SG&A Spending Patterns Compared